Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

Kensei Tobinai, Takashi Watanabe, Michinori Ogura, Yasuo Morishima, Tomomitsu Hotta, Kenichi Ishizawa, Kuniaki Itoh, Shin Ichiro Okamoto, Masafumi Taniwaki, Norifumi Tsukamoto, Hirokazu Okumura, Takashi Terauchi, Shigeru Nawano, Masaki Matsusako, Yoshihiro Matsuno, Shigeo Nakamura, Shigeo Mori, Yasuo Ohashi, Masaki Hayashi, Keigo Endo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Fingerprint Dive into the research topics of 'Japanese phase II study of <sup>90</sup>Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences